Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma
Transplantation and Cellular Therapy(2021)
Abstract
•We reviewed outcomes in 20 patients with secondary central nervous system (CNS) lymphoma undergoing allogeneic blood or marrow transplantation.•All patients received nonmyeloablative conditioning and post-transplantation cyclophosphamide.•Prolonged disease-free survival was achieved in ∼50% of patients.•Myeloablative conditioning and CNS radiotherapy were not required for remission.
MoreTranslated text
Key words
CNS lymphoma,Post-transplantation cyclophosphamide,Haploidentical stem cell transplantation
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined